Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders
- Conditions
- Smoking Cessation
- Interventions
- Registration Number
- NCT01456936
- Lead Sponsor
- Pfizer
- Brief Summary
This study is being conducted to assess varenicline and bupropion as aids to smoking cessation treatment in subjects with and without an established diagnosis of major psychiatric disorder and to characterize the neuropsychiatric safety profile (pre-specified adverse events (AEs) in both of these populations).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 8144
- Male or female cigarette smokers, 18- 75 years, motivated to stop smoking and considered suitable for a smoking cessation attempt.
- Smoked an average of at least 10 cigarettes per day during past year and during the month prior to the screening visit, and exhaled carbon monoxide (CO) >10 ppm at screening.
- For Neuropsychiatric cohort- subjects must have proper diagnosis as outlined in protocol.
-
Subjects with a past or current diagnosis of one of the following disorders:
a. Psychotic Disorders:
-
Schizophreniform
-
Delusional Disorder
-
Psychotic Disorder NOS b. All Delirium, Dementia, and Amnestic and Other Cognitive Disorders c. All Substance Induced Disorders (Other than nicotine)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description placebo Placebo Subjects randomized to placebo will receive placebo treatments for all three study drugs. Blinded placebo will be provided for varenicline, bupropion hydrochloride and transdermal nicotine patch (NRT). In addition, subjects will receive blinded placebo treatments for the study drugs they are not randomized to receive. varenicline varenicline tartrate - bupropion bupropion hydrochloride - Nicotine Replacement Therapy Patch Nicotine Replacement Therapy Patch -
- Primary Outcome Measures
Name Time Method Occurrence of Neuropsychiatric (NPS) Adverse Events (AE) - the Primary Study Endpoint Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days. The primary safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide.
Estimated NPS AE Rate (%), by Cohort Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days. The primary safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Estimated NPS AE rate (%) was calculated based on least-squares means analysis.
- Secondary Outcome Measures
Name Time Method Occurrence of the Components of the NPS AE Primary Endpoint, Non-psychiatric History Cohort Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days. The safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below.
Occurrence of Severe-only NPS AEs in the Primary Endpoint, by Cohort Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days. The primary safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.
Occurrence of the Components of the NPS AE Primary Endpoint, Psychiatric History Cohort Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days. The safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below.
Occurrence of the Components of NPS AE Primary Endpoint (Overall) Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days. The NPS AE composite results (as previously described) are for the two cohorts combined and are presented below.
Occurrence of the Components of the Observed Severe-only NPS AE Primary Endpoint, Non-psychiatric History Cohort Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days. The safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.
Occurrence of the Components of the Observed Severe-only NPS AE Primary Endpoint, Psychiatric History Cohort Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days. The safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.
Occurrence of the Components of Severe-only NPS AE Endpoint (Overall) Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days. The NPS AE endpoint was the occurrence of at least 1 treatment-emergent "severe" AE of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least 1 treatment-emergent "severe" AE of agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.
Hospital Anxiety and Depression Scale (HADS) Total Score, Non-psychiatric History Cohort Baseline to Week 24 The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.
HADS Total Score, Psychiatric History Cohort Baseline to Week 24 The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.
HADS Total Score (Overall) Baseline to Week 24 The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.
Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C-SSRS) - Non-psychiatric History Cohort Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days. The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent". Answers at screening are for lifetime history. Answers for all other visits are since last visit.The scale is also used to record any completed suicides.
Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C-SSRS) - Psychiatric History Cohort Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days. The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent". Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides.
CO-Confirmed Continuous Abstinence for Weeks 9 Through 12, Non-psychiatric History Cohort Week 9 through Week 12 A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).
Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C-SSRS) - Overall Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days. The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent". Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides.
Clinical Global Impression of Improvement (CGI-I), "No Change" Rating by Visit Baseline to Week 24 The CGI-I is a clinician rated instrument that measures change in participant's psychiatric condition (or lack thereof in the stratum without psychiatric disorders) on a 7 point scale ranging from 1 (very much improved) to 7 (very much worse), with 4 = no change. The ratings were applicable even to those without psychiatric diagnoses (eg, those with no psychiatric symptoms would be rated as "normal, not at all ill" on the CGI-S at baseline and assuming no psychiatric symptoms emerge during the trial, would be rated as "no change" on the CGI-I at follow-up visits). For those participants with a psychiatric diagnosis, the clinician should rate the severity of the mental illness with respect to the clinician's experience with the psychiatric population to which the participant belongs.
CO-Confirmed Continuous Abstinence for Weeks 9 Through 12, Psychiatric History Cohort Week 9 through Week 12 A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).
CO-Confirmed Continuous Abstinence for Weeks 9 Through 12 (Overall) Week 9 through Week 12 A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).
CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Non-psychiatric History Cohort Week 9 through Week 24 A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).
CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Psychiatric History Cohort Week 9 through Week 24 A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).
CO-confirmed Continuous Abstinence From Week 9 Through Week 24 (Overall) Week 9 through Week 24 A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).
7-Day Point Prevalence of Abstinence, Non-psychiatric History Cohort 24 Weeks A responder to this endpoint requires the answer "no" to both questions 3 and 6 on the nicotine use inventory at that specific visit.
NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?7-Day Point Prevalence of Abstinence, Psychiatric History Cohort 24 Weeks A responder to this endpoint requires the answer "no" to both questions 3 and 6 on the nicotine use inventory at that specific visit.
NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?7-Day Point Prevalence of Abstinence (Overall) 24 Weeks A responder to this endpoint requires the answer "no" to both questions 3 and 6 on the nicotine use inventory at that specific visit.
NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?
Trial Locations
- Locations (151)
Pharmacology Research Institute
🇺🇸Newport Beach, California, United States
Belmont Center for Comprehensive Treatment
🇺🇸Philadelphia, Pennsylvania, United States
Centro de Investigacion Clinica WM
🇦🇷Mataderos, Buenos Aires, Argentina
Specializirana Bolnitsa za Aktivno Lechenie na Belodrobni Bolesti-Troyan EOOD,
🇧🇬Troyan, Bulgaria
Clinica de Enfermedades Cronicas y de Procedimientos Especiales S.C.
🇲🇽Morelia, Michoacan, Mexico
Centro Respiratorio Integral (CENRESIN Ltda.)
🇨🇱Quillota, Valparaiso, V Region, Chile
Centro de Estudios Clinicos y Especialidades Medicas S.C.
🇲🇽Monterrey, Nuevo Leon, Mexico
Heartland Research Associates, LLC
🇺🇸Wichita, Kansas, United States
Hospital Regional de Talca, Unidad de Enfermedades Respiratorias
🇨🇱Talca, Maule, Chile
Vince and Associates Clinical Research
🇺🇸Overland Park, Kansas, United States
CCBR A/S
🇩🇰Vejle, Denmark
Medical Research Associates
🇨🇦Mississauga, Ontario, Canada
Neuropsychiatric Research Center of Southwest Florida
🇺🇸Fort Myers, Florida, United States
North County Clinical Research
🇺🇸Oceanside, California, United States
Ocala Psychiatric Associates
🇺🇸Ocala, Florida, United States
Northwest Neurobehavioral Health
🇺🇸Meridian, Idaho, United States
Jacksonville Center for Clinical Research
🇺🇸Jacksonville, Florida, United States
Sun Valley Research Center
🇺🇸Imperial, California, United States
Omega Clinical Trials
🇺🇸La Habra, California, United States
Northwest Behavioral Research Center
🇺🇸Marietta, Georgia, United States
Comprehensive Psychiatric Care
🇺🇸Norwich, Connecticut, United States
Renstar Medical Research
🇺🇸Ocala, Florida, United States
Broward Research Group
🇺🇸Hollywood, Florida, United States
UMBAL Sveti Georgi EAD, Klinika po psihiatriya
🇧🇬Plovdiv, Bulgaria
Central Kentucky Research Associates, Inc.
🇺🇸Lexington, Kentucky, United States
Southeastern PA Medical Institute
🇺🇸Broomall, Pennsylvania, United States
Wake Research Associates, LLC
🇺🇸Raleigh, North Carolina, United States
AMR-Baber Research Inc.
🇺🇸Naperville, Illinois, United States
Milford Emergency Associates, Incorporated
🇺🇸Milford, Massachusetts, United States
Maine Research Associates
🇺🇸Auburn, Maine, United States
Community Clinical Services
🇺🇸Lewiston, Maine, United States
Precise Research Centers
🇺🇸Flowood, Mississippi, United States
Mercy Health Research
🇺🇸St.Louis, Missouri, United States
Global Medical Institutes LLC; Princeton Medical Institute Woodlands Professional Building
🇺🇸Princeton, New Jersey, United States
InSite Clinical Research
🇺🇸DeSoto, Texas, United States
MHATNP Sveti Naum SJsc.
🇧🇬Sofia, Bulgaria
Clinical NeuroScience Solutions, Inc.
🇺🇸Memphis, Tennessee, United States
PMG Research of Raleigh, LLC d/b/a PMG Research of Cary
🇺🇸Cary, North Carolina, United States
Clinical Research Associates of Tidewater
🇺🇸Norfolk, Virginia, United States
Monash Alfred Psychiatry Research Centre
🇦🇺Melbourne, Victoria, Australia
Lincoln Research
🇺🇸Lincoln, Rhode Island, United States
Social Psychiatry Research Institute Clinical Trials LLC
🇺🇸Brooklyn, New York, United States
Tooley Group
🇺🇸Cary, North Carolina, United States
Midwest Clinical Research Center
🇺🇸Dayton, Ohio, United States
Volunteer Research Group
🇺🇸Knoxville, Tennessee, United States
Peninsula Psychotherapy Center, LLC
🇺🇸Newport News, Virginia, United States
Irmandade da Santa Casa de Misericórdia Porto Alegre
🇧🇷Porto Alegre, RS, Brazil
Centro Medico Dra. De Salvo
🇦🇷Ciudad Autonoma de Bs. As, Buenos Aires, Argentina
SBALPFZ - Ruse EOOD
🇧🇬Ruse, Bulgaria
Royal Brisbane & Women's Hospital
🇦🇺Herston, Queensland, Australia
University of Ottawa Heart Institute
🇨🇦Ottawa, Ontario, Canada
Hospital Sao Lucas da PUCRS - Uniao Brasileira de Educacao e Assistencia
🇧🇷Porto Alegre, RS, Brazil
Dr. Felix Yaroshevsky
🇨🇦Toronto, Ontario, Canada
Clinical Mental Hospital #12 of Moscow Healthcare Department
🇷🇺Moscow, Russian Federation
FSBI "Saint-Petersburg Scientific Research Psychoneurological Institute n.a. V.M. Bekhterev" of MoH
🇷🇺Saint-Petersburg, Russian Federation
The University of Texas M.D. Anderson Cancer Center
🇺🇸Houston, Texas, United States
FutureSearch Clinical Trials, L.P.
🇺🇸Austin, Texas, United States
University of Wisconsin School of Medicine and Public Health
🇺🇸Madison, Wisconsin, United States
Clinical Research Atlanta
🇺🇸Stockbridge, Georgia, United States
A Professional Corporation dba The Center for Sexual Health
🇺🇸Metairie, Louisiana, United States
Coastal Carolina Research Center
🇺🇸Mount Pleasant, South Carolina, United States
Synergy Clinical Research of Escondido
🇺🇸Escondido, California, United States
Coastal Clinical Research, Inc.
🇺🇸Mobile, Alabama, United States
Neuropsychiatric Research Center of Orange County
🇺🇸Orange, California, United States
David Geffen School of Medicine at University of California, Los Angeles
🇺🇸Los Angeles, California, United States
Pacific Treatment and Research Center UC San Diego Health System
🇺🇸La Jolla, California, United States
California Neuroscience Research Medical Group, Inc.
🇺🇸Sherman Oaks, California, United States
Clinical Neuroscience Solutions,Inc.
🇺🇸Jacksonville, Florida, United States
Clinical Neuroscience Solutions, Inc
🇺🇸Orlando, Florida, United States
Advanced Clinical Research
🇺🇸Meridian, Idaho, United States
American Health Network of IN, LLC
🇺🇸Indianaopolis, Indiana, United States
Rahim Shafa, MD
🇺🇸Milford, Massachusetts, United States
Wake Internal Medicine Consultants, Inc
🇺🇸Raleigh, North Carolina, United States
University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
🇺🇸New Brunswick, New Jersey, United States
Regional Clinical Research, Inc.
🇺🇸Endwell, New York, United States
East Side Clinical Laboratory
🇺🇸Lincoln, Rhode Island, United States
CRI Worldwide, LLC
🇺🇸Philadelphia, Pennsylvania, United States
New Orleans Center for Clinical Research
🇺🇸Knoxville, Tennessee, United States
University of Wisconsin Hospital and Clinics
🇺🇸Madison, Wisconsin, United States
Hospital de Messejana Dr. Carlos Alberto Studart Gomes
🇧🇷Fortaleza, CE, Brazil
Mental Health Center "Prof. Dr. Ivan Temkov-Bourgas" Ltd.
🇧🇬Bourgas, Bulgaria
Hospital e Maternidade Celso Pierro - PontifÃcia Universidade Católica de Campinas - Campus II
🇧🇷Campinas, SP, Brazil
Instituto Jaqueline Scholz Issa e Mario Issa de cardiologia S/C Ltda
🇧🇷Sao Paulo, SP, Brazil
MBAL Dr. Hristo Stambolski EOOD
🇧🇬Kazanlak, Bulgaria
UMBAL Dr. Georgi Stranski EAD,
🇧🇬Pleven, Bulgaria
DPB Sv. Ivan Rilski
🇧🇬Novi Iskar, Bulgaria
Meditsinski Tsentar ¿Sveti Naum¿ EOOD
🇧🇬Sofia, Bulgaria
Tsentar za psihichno zdrave - Ruse EOOD
🇧🇬Ruse, Bulgaria
Hamilton Medical Research Group
🇨🇦Hamilton, Ontario, Canada
Canadian Phase Onward Inc.
🇨🇦Toronto, Ontario, Canada
Centre for Addiction and Mental Health (CAMH)
🇨🇦Toronto, Ontario, Canada
Centre of Addiction and Mental Health Pharmacy
🇨🇦Toronto, Ontario, Canada
Diex Research Sherbrooke Inc.
🇨🇦Sherbrooke, Quebec, Canada
Mehiläinen Leppävaara
🇫🇮Espoo, Finland
PEL, Psykiatrian ErikoiLääkärit
🇫🇮Turku, Finland
Savon Psykiatripalvelu Oy
🇫🇮Kuopio, Finland
Mehiläinen Nummela
🇫🇮Nummela, Finland
Oulu Mentalcare
🇫🇮Oulu, Finland
Porin Lääkäritalo Oy
🇫🇮Pori, Finland
Klinische Forschung Berlin-Mitte GmbH
🇩🇪Berlin, Germany
emovis GmbH
🇩🇪Berlin, Germany
Universitaetsklinikum Freiburg
🇩🇪Freiburg, Germany
ZSL - Zentrum fuer Medizinische Studien Leipzig GmbH
🇩🇪Leipzig, Sachsen, Germany
Klinische Forschung Hamburg GmbH
🇩🇪Hamburg, Germany
Universitaetsklinik Tuebingen
🇩🇪Tuebingen, Germany
Centro Respiratorio de Mexico S.C.
🇲🇽Mexico, D.f., Mexico
Ludwig Maximilians-Universitaet Muenchen
🇩🇪Muenchen, Germany
Lakeland Clinical Trials
🇳🇿Rotorua, New Zealand
Consultarios de Medicina Especializada del Sector Privado
🇲🇽Colonia Hipodromo Condesa, Mexico DF, Mexico
FSBI "Federal Medical Research Center of Psychiatry and Addiction Medicine"
🇷🇺Moscow, Russian Federation
FSBI Moscow Scientific Research Institute of Psychiatry"
🇷🇺Moscow, Russian Federation
Moscow State Public Healthcare Institution Mental Clinical Hospital #1 n.a. N.A. Alexeeva
🇷🇺Moscow, Russian Federation
Clinical Psychiatric Hospital #1 of Nizhni Novgorod
🇷🇺Nizhni Novgorod, Russian Federation
SBEI HPE ##Smolensk State Medical Academy## of MoH of RF
🇷🇺Smolensk, Russian Federation
St. Petersburg State Healthcare Institution, St. Nikolay Chudotvorets Mental Hospital
🇷🇺St. Petersburg, Russian Federation
Smolensk State Medical Academy of Ministry of Healthcare of Russian Federation
🇷🇺Smolensk, Russian Federation
State Healthcare Institution "Psychoneurological Dispensary #2
🇷🇺St. Petersburg, Russian Federation
Psychiatricka ambulancia, Mentum, s.r.o.
🇸🇰Bratislava, Slovakia
Vavrusová consulting s.r.o., Nestatna psychiatricka ambulancia, MUDr. Livia Vavrusova, PhD
🇸🇰Bratislava, Slovakia
Psychiatricka ambulancia MUDr. Nada Kuriackova, s.r.o.
🇸🇰Levice, Slovakia
Psychiatricka ambulancia, PsychoLine s.r.o.
🇸🇰Rimavska Sobota, Slovakia
Nemocnica s poliklinikou sv. Barbory Roznava a.s.
🇸🇰Roznava, Slovakia
Flexivest Fourteen Research Center
🇿🇦Bellville, Cape Town, South Africa
Vista Clinic
🇿🇦Centurion, Gauteng, South Africa
Worthwhile Clinical Trials
🇿🇦Benoni, Johannesburg, Gauteng, South Africa
Soweto Clinical Trials Centre
🇿🇦Johannesburg, Gauteng, South Africa
Randles Road Medical Centre
🇿🇦Durban, Kwazulu Natal, South Africa
I Engelbrecht Research Pty, Ltd
🇿🇦Lyttelton, Gauteng, South Africa
Midrand Medical Centre
🇿🇦Midrand, Gauteng, South Africa
Private Practice
🇿🇦Durban, Kwa-Zulu Natal, South Africa
Hospital de La Santa Creu I Sant Pau
🇪🇸Barcelona, Spain
Dr John OBrien Incorporated
🇿🇦Cape Town, Western Cape, South Africa
Hospital General Universitari Vall d'Hebron
🇪🇸Barcelona, Spain
Hospital San Pedro de Alcantara
🇪🇸Caceres, Spain
Hospital Clinic I Provincial
🇪🇸Barcelona, Spain
Unidad Especializada en Tabaquismo de la Comunidad de Madrid
🇪🇸Madrid, Spain
Centro de Salud Torrero La Paz
🇪🇸Zaragoza, Spain
NoesisPharma Research
🇺🇸Phoenix, Arizona, United States
University of Colorado Denver, Anschutz Medical Campus , Behavioral Health and Wellness Program
🇺🇸Aurora, Colorado, United States
Western Affiliated Research Institute
🇺🇸Denver, Colorado, United States
Meridien Research
🇺🇸Tampa, Florida, United States
Davis Clinic, Incorporated
🇺🇸Indianapolis, Indiana, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Goldpoint Clinical Research, LLC
🇺🇸Indianapolis, Indiana, United States
Kentucky Research Group
🇺🇸Louisville, Kentucky, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
University of Minnesota- TC
🇺🇸Minneapolis, Minnesota, United States
Clinical Research Associates, Inc.
🇺🇸Nashville, Tennessee, United States
James G. Kyser, MD
🇺🇸Nashville, Tennessee, United States
Oregon Health and Sciences University
🇺🇸Portland, Oregon, United States
The Center for Pharmaceutical Research, PC
🇺🇸Kansas City, Missouri, United States